
Patients with Hodgkin lymphoma receiving brentuximab vedotin may safely skip PET2 scans without impacting outcomes.


coremsg

Recent data suggest that performing interim PET-CT in patients receiving frontline brentuximab vedotin plus chemotherapy generally does not affect patient management or outcomes.

Safely Skip PET2 After Brentuximab in Hodgkin Lymphoma?

safety-of-skipping-pet2-after-brentuximab-in-hodgkin-lymphoma


Safety of Skipping PET2 After Brentuximab in Hodgkin Lymphoma
